tiprankstipranks
Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
Holding GB:0RG8?
Track your performance easily

Sartorius Stedim Biotech (0RG8) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0RG8 Analyst Ratings

Moderate Buy
6Ratings
3 Buy
3 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Sartorius
Stedim Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0RG8 Stock 12 Month Forecast

Average Price Target

€216.33
▲(23.63% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €216.33 with a high forecast of €270.00 and a low forecast of €155.00. The average price target represents a 23.63% change from the last price of €174.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"154":"€154","271":"€271","183.25":"€183.3","212.5":"€212.5","241.75":"€241.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":216.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€216.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[154,183.25,212.5,241.75,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,191.83,197.84307692307692,203.85615384615386,209.86923076923077,215.8823076923077,221.89538461538461,227.90846153846155,233.92153846153846,239.9346153846154,245.9476923076923,251.96076923076924,257.9738461538461,263.98692307692306,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,191.83,193.7146153846154,195.5992307692308,197.48384615384617,199.36846153846156,201.25307692307695,203.1376923076923,205.0223076923077,206.90692307692308,208.79153846153847,210.67615384615385,212.56076923076924,214.44538461538463,{"y":216.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,191.83,188.99692307692308,186.16384615384615,183.33076923076925,180.49769230769232,177.6646153846154,174.83153846153846,171.99846153846156,169.16538461538462,166.3323076923077,163.49923076923076,160.66615384615386,157.83307692307693,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":200.15,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.22,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.55,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.07,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.53,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.04,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.65,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.34,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.53,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":179.72,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.11,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€270.00Average Price Target€216.33Lowest Price Target€155.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan
€275€240
Buy
37.16%
Upside
Reiterated
07/29/24
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR240 at JPMorganJPMorgan analyst Richard Vosser lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR240.00 (from EUR275.00) while maintaining a Overweight rating.
Bernstein
€134
Sell
-23.42%
Downside
Downgraded
07/29/24
Sartorius Stedim Biotech (0RG8) was downgraded to a Sell Rating at Bernstein
Berenberg Bank
€182
Buy
4.01%
Upside
Reiterated
07/24/24
Berenberg Bank Sticks to Its Buy Rating for Sartorius Stedim Biotech (0RG8)
HSBC
€390€360
Buy
105.73%
Upside
Reiterated
04/19/24
Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR360 at HSBCHSBC analyst Sezgi Oezener lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR360.00 (from EUR390.00) while maintaining a Buy rating.

Best Analysts Covering Sartorius Stedim Biotech

Which Analyst Should I Follow If I Want to Buy GB:0RG8 and Sell After:
1 Month
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+5.76%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +5.76% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
57%
Average Return
+2.29%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.29% per trade.
1 Year
Success Rate
3/6 ratings generated profit
50%
Average Return
-9.55%
downgraded a sell rating 4 months ago
Copying Delphine Le Louet's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.55% per trade.
2 Years
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
-19.52%
downgraded a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -19.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RG8 Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
3
2
1
2
1
Buy
5
4
3
3
6
Hold
5
4
3
4
5
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
13
11
8
10
12
In the current month, 0RG8 has received 7 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0RG8 average Analyst price target in the past 3 months is €216.33.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0RG8 Financial Forecast

0RG8 Earnings Forecast

Next quarter’s earnings estimate for 0RG8 is €0.97 with a range of €0.72 to €1.38. The previous quarter’s EPS was €0.76. 0RG8 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year 0RG8 has Underperformed its overall industry.
Next quarter’s earnings estimate for 0RG8 is €0.97 with a range of €0.72 to €1.38. The previous quarter’s EPS was €0.76. 0RG8 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year 0RG8 has Underperformed its overall industry.

0RG8 Sales Forecast

Next quarter’s sales forecast for 0RG8 is €710.61M with a range of €700.80M to €723.55M. The previous quarter’s sales results were €655.40M. 0RG8 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 44.59% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.
Next quarter’s sales forecast for 0RG8 is €710.61M with a range of €700.80M to €723.55M. The previous quarter’s sales results were €655.40M. 0RG8 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 44.59% of the time in the same period. In the last calendar year 0RG8 has Outperformed its overall industry.

0RG8 Stock Forecast FAQ

What is GB:0RG8’s average 12-month price target, according to analysts?
Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is €216.33.
    What is GB:0RG8’s upside potential, based on the analysts’ average price target?
    Sartorius Stedim Biotech has 23.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sartorius Stedim Biotech a Buy, Sell or Hold?
          Sartorius Stedim Biotech has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Sartorius Stedim Biotech’s share price target?
            The average share price target for Sartorius Stedim Biotech is €216.33. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €270.00 ,and the lowest forecast is €155.00. The average share price target represents 23.63% Increase from the current price of €174.983.
              What do analysts say about Sartorius Stedim Biotech?
              Sartorius Stedim Biotech’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Sartorius Stedim Biotech?
                To buy shares of GB:0RG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis